Drugs / RSM01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05118386 | Nov 2021 → Aug 2022 | respiratory syncytial virus infectious disease | Gates Medical Research Institute | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-08-14 | SK Bioscience Co., Ltd. | Regulatory SK bioscience Advances Development of Next-Generation Infectious Disease Prevention Platform with Global Phase 1b CTA Submission for RSV Preventive Antibody Candidate skbioscience.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-08-14 | SK Bioscience Co., Ltd. | SK bioscience Advances Development of Next-Generation Infectious Disease Prevention Platform with Global Phase 1b CTA Submission for RSV Preventive Antibody Candidate skbioscience.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RSM01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05118386 ↗ |
| Modality | Monoclonal antibody | “RSM01, a monoclonal antibody targeting RSV” NCT05118386 ↗ |
| Route | Intramuscular | “single intravenous or intramuscular doses of RSM01” NCT05118386 ↗ |
| Route | Intravenous | “single intravenous or intramuscular doses of RSM01” NCT05118386 ↗ |